Hildenbrand R, Dilger I, Hörlin A, Stutte H J
Senckenbergisches Zentrum der Pathologie, Klinikum der J. W. Goethe-Universität, Frankfurt, FRG.
Pathol Res Pract. 1995 Jun;191(5):403-9. doi: 10.1016/S0344-0338(11)80726-0.
Urokinase plasminogen activator (uPA) is a proteolytic enzyme implicated in cancer invasion and tumor progression. Urokinase PA and its inhibitor (PAI-1) appear to be new and independent prognostic markers in breast cancer. To investigate how uPA- and PAI-1-levels correlate with angiogenesis and tumor vessel invasion, we counted microvessels and their tumor invasion and determined the uPA- and PAI-1 levels in 42 primary invasive breast carcinomas. 20 Patients had no lymph node metastasis at the time of surgery, while 22 patients had positive nodes. Using light microscopy, we highlighted the vessels by staining their endothelial cells immunocytochemically for CD31 and Factor VIII. After gaining tumor tissue extracts, we determined the uPA- and PAI-1-levels by ELISA. A positive correlation between microvessel density, angioinvasion and uPA- and PAI-1-levels was found. We speculate that high uPA levels may induce tumor neovascularisation, angioinvasion and may cause tumor progression and metastasis. The degradation of the vessel wall by uPA causes a leak. This wall defect may, on the one hand, be the stimulus for endothelial cell proliferation and formation of new blood vessels and, on the other hand, it may be the place of tumor cell entry.
尿激酶型纤溶酶原激活剂(uPA)是一种与癌症侵袭和肿瘤进展相关的蛋白水解酶。尿激酶型PA及其抑制剂(PAI-1)似乎是乳腺癌新的独立预后标志物。为了研究uPA和PAI-1水平如何与血管生成和肿瘤血管侵袭相关,我们对42例原发性浸润性乳腺癌的微血管及其肿瘤侵袭情况进行了计数,并测定了uPA和PAI-1水平。20例患者在手术时无淋巴结转移,而22例患者有阳性淋巴结。我们通过免疫细胞化学方法对内皮细胞进行CD31和因子VIII染色,利用光学显微镜突出显示血管。获取肿瘤组织提取物后,我们通过酶联免疫吸附测定法测定uPA和PAI-1水平。我们发现微血管密度、血管侵袭与uPA和PAI-1水平之间呈正相关。我们推测,高uPA水平可能诱导肿瘤新生血管形成、血管侵袭,并可能导致肿瘤进展和转移。uPA对血管壁的降解会导致渗漏。这种管壁缺陷一方面可能是内皮细胞增殖和新血管形成的刺激因素,另一方面可能是肿瘤细胞进入的部位。